%0 Journal Article
%T Osimertinib Regresses an EGFR-Mutant Cisplatinum- Resistant Lung Adenocarcinoma Growing in the Brain in Nude Mice
%A Hiroaki Kimura
%A Hiromichi Oshiro
%A Hiroyuki Tsuchiya
%A Katsuhiro Hayashi
%A Kentaro Igarashi
%A Kentaro Miyake
%A Michael Bouvet
%A Ming Zhao
%A Norihiko Sugisawa
%A Norio Yamamoto
%A Robert M Hoffman
%A Shinji Miwa
%A Shree Ram Singh
%A Takashi Higuchi
%A Yuki Katsuya
%A Zhiying Zhang
%J Archive of "Translational Oncology".
%D 2019
%R 10.1016/j.tranon.2019.01.007
%X The goal of the present study was to determine the efficacy of osimertinib (AZD9291), a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor for the treatment of aggressive EGFR-mutant non-small cell lung cancer (NSCLC), compared to cisplatinum (CDDP)£¿+£¿pemetrexed (PEM). The NSCLC cell line PC-9 expressing green fluorescence protein (PC-9-GFP) was implanted in the brain of nude mice and was treated with CDDP + PEM or AZD9291. Tumors were observed by non-invasive fluorescence imaging. AZD9291 treatment caused tumor regression in contrast to CDDP + PEM which had only a slight inhibitory effect. These results suggest that AZD9291 is a promising clinical option for NSCLC patients with brain metastasis
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6393699/